250 related articles for article (PubMed ID: 37227456)
1. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
Despang P; Schikora M; Doehner W
Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
[TBL] [Abstract][Full Text] [Related]
3. A polypill strategy to improve adherence: results from the FOCUS project.
Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
[TBL] [Abstract][Full Text] [Related]
4. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Ostovaneh MR; Poustchi H; Hemming K; Marjani H; Pourshams A; Nateghi A; Majed M; Navabakhsh B; Khoshnia M; Jaafari E; Mohammadifard N; Malekzadeh F; Merat S; Sadeghi M; Naemi M; Etemadi A; Thomas GN; Sarrafzadegan N; Cheng KK; Marshall T; Malekzadeh R
Eur J Prev Cardiol; 2015 Dec; 22(12):1609-17. PubMed ID: 25230980
[TBL] [Abstract][Full Text] [Related]
5. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
[TBL] [Abstract][Full Text] [Related]
6. The concept of the polypill in the prevention of cardiovascular disease.
Wiley B; Fuster V
Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
[TBL] [Abstract][Full Text] [Related]
7. The polypill strategy in cardiovascular disease prevention: It's time for its implementation.
Di Fusco SA; Aquilani S; Spinelli A; Alonzo A; Matteucci A; Castello L; Imperoli G; Colivicchi F
Prog Cardiovasc Dis; 2023; 79():37-40. PubMed ID: 36931543
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
[TBL] [Abstract][Full Text] [Related]
9. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
Roy A; Naik N; Srinath Reddy K
Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
[TBL] [Abstract][Full Text] [Related]
10. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
Bramlage P; Sims H; Minguet J; Ferrero C
Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
[TBL] [Abstract][Full Text] [Related]
11. The feasibility of polypill for cardiovascular disease prevention in Asian Population.
Sukonthasarn A; Chia YC; Wang JG; Nailes J; Buranakitjaroen P; Van Minh H; Verma N; Hoshide S; Shin J; Turana Y; Tay JC; Teo BW; Siddique S; Sison J; Zhang YQ; Wang TD; Chen CH; Kario K
J Clin Hypertens (Greenwich); 2021 Mar; 23(3):545-555. PubMed ID: 33086429
[TBL] [Abstract][Full Text] [Related]
12. Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.
Lopez-Lopez JP; Gonzalez AM; Lanza P; Lopez-Jaramillo P
Vasc Health Risk Manag; 2023; 19():605-615. PubMed ID: 37719697
[TBL] [Abstract][Full Text] [Related]
13. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
[TBL] [Abstract][Full Text] [Related]
14. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
[TBL] [Abstract][Full Text] [Related]
15. Polypill Strategy in Secondary Cardiovascular Prevention.
De la Rosa A; Arrington K; Desai R; Acharya PC
Curr Cardiol Rep; 2024 May; 26(5):443-450. PubMed ID: 38557814
[TBL] [Abstract][Full Text] [Related]
16. [Management of different cardiovascular risk factors with a combination tablet (polypill)].
Bramlage P; März W; Westermann D; Weisser B; Wirtz JH; Zeymer U; Baumgart P; van Mark G; Laufs U; Krämer BK; Unger T
Herz; 2018 May; 43(3):246-257. PubMed ID: 28341983
[TBL] [Abstract][Full Text] [Related]
17. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
[TBL] [Abstract][Full Text] [Related]
18. Polypill-based strategy vs. usual care for secondary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials.
Rivera A; Campos B; Ceolin S; Godoi A; Castanha E; Campello Jorge CA; Cardoso R
Eur J Prev Cardiol; 2023 Nov; 30(16):1828-1837. PubMed ID: 37490769
[TBL] [Abstract][Full Text] [Related]
19. Polypill Trials for Stroke Prevention-Main Results, Critical Appraisal, and Implications for US Population.
Ibraheem M; Goldstein LB
Curr Neurol Neurosci Rep; 2020 Apr; 20(5):10. PubMed ID: 32296941
[TBL] [Abstract][Full Text] [Related]
20. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
